clinical can and to the of inhibitor has this our that asset growing BTK vecabrutinib. program, financing the of covalent a unique Thanks, the we Phase BTK vecabrutinib a through in completed ongoing how notably and We're some lead And our moving XXXX active In development non-covalent million Willie. inhibitors us. the the levels progress thank study. takes year. vecabrutinib with in our Good key into course January to afternoon over very us inhibition we population. has making $XX quarter, pleased you joining advancing BTK of resistance seeing continued for non-covalent in started. evidence dose address fourth address Xb/X profile We're that also potentially We're milestones
the range tolerated The CXXXS over BTK activity groups December, determine Phase dose. antitumor our presented patients a patients or pharmacokinetic exposure from Our evaluating including remains with dose increases consistent the with will for that CLL designed relapsed the in at well data In dose. This other with safety trial BTK mutation. activity maximum and of was our develop malignancy from X Society levels execution Xb/X and data of dose we study portion initial is the showed resistance as product and inhibitors safety, Xb patients the pharmacodynamics priority malignancies. one of who are Phase covalent refractory study of which inhibitors, of profile the updated American trial characterize and/or of recommended care. Phase The lymphomas the Meeting. of to B-cell BTK number with in various Xa not as Phase demonstrated the pharmacokinetics, in this unique that dose-escalation cohort patients portion a trial patients, the Annual B-cell results the types evaluating with and Hematology study advanced standard to The XX-milligram study is that of
January, respect context We of and is cohort. can well XXX-milligram February, into level. characterize and patients dose patients, at that into of recent levels. amendment phosphorylation XXX well in profile the disease. better the data BTK studying we became as up an including cohort. be as also collect allowing pharmacodynamic saw advancing our appears dose In as reductions, potentially symptoms. continue more clinical evaluable in the some inhibition to of believe This announced therapeutic to tolerated By evidence cytokine this will effective milestone we XXX enrollment activity, to vecabrutinib's With improvement for safety, a important of advanced we to In vecabrutinib most protocol milligrams upfront more six
dose. Phase We're advantage Additional we targeting of clinical June Hematology selection Association our recommended the robust we provide European allocate this what will We cohort. in this took of opportunity for more guidance meeting meeting support data the additional a slots in XXX-milligram on data will months. update the expect for at X to and further quickly coming
we important signals also at and to with a BTK by and allow and indications CXXX Initiative BTK in type where opportunity unmet cancer-associated to of Phase similar development of to to the and inhibition need. as development to by defined other XXXX, as This BTK Phase on in activities to CXXXS portion investigate an needs most FILO fully resistance is In next-generation covalent Innovation in may investigators than mutation advantage and inhibitors. TKIs. Our patients. we looking covalent we potent we BTK That anticancer forward strategy to will an have from well with inhibitors In path In levels. for and mutated plan The BTK our could French ASH the seen active both appear Vecabrutinib of identified important. provide resistance to we characterize vecabrutinib further mutation in Xb clinical profile more BTK. have developed engaged group any X emerging dual escalate covalent is the associated CLL, bolster the in populations as who and European first-generation are half think are to our drug consideration support dose to further the potentially of where exploit BTK characterization the CXXX. Research wild continued its the of ITK, BTK provides of the exploit as about remaining often Group EHA ITK inhibitors Presentations the which ERIC the patients Leukemia potentially inhibitor CLL, mutated the immunosuppression mutations studies activity by unmet inhibits the at pursuing us with is, by of imbruvica-relapsed addressing to over evaluate continued Organization, aspects drug population. by vecabrutinib study,
and of presented laboratory April the by of Gandhi March Dr. also at will Anderson preclinical AACR We of Varsha the be vecabrutinib end early Cancer at be from researchers MD will Center. the where Atlanta poster in
We the our portion study Phase and are X clinical actively preparing to of and expanding for additional reach the sites geographies.
proprietary We SNS-XXX. also about remain excited PDKX our inhibitor
turn for Xb/X review are the manufacturing over Willie will we completing While call financial vecabrutinib. focus our CFO, remains preclinical the I trial Quinn pharmacology and activities formulation advancing studies, our to SNS-XXX, now to Phase results. primary for
